MAIA Biotechnology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated May 25, 2023, reports on the results of MAIA Biotechnology, Inc.'s 2023 Annual Meeting of Stockholders. The Company is an emerging growth company incorporated in Delaware and trades on the NYSE American under the symbol "MAIA."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
As of the record date of March 30, 2023, there were 10,996,404 shares of common stock outstanding. Approximately 59.16% of these shares were present at the meeting, establishing a quorum. The following matters were approved:
- Election of Directors: Stockholders re-elected Ms. Louie Ngar Yee and Mr. Steven Chaouki to three-year terms expiring in 2026. Both nominees received over 6.05 million votes "For."
- Ratification of Auditors: Stockholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023. The proposal received 6,502,742 votes "For" versus 3,091 "Against."
- Equity Incentive Plan Amendment: Stockholders approved an amendment to the 2021 Equity Incentive Plan. This amendment authorizes an automatic annual increase in the share reserve, commencing on the approval date and continuing through January 1, 2032. The increase will equal 10% of the total fully diluted shares outstanding on the preceding December 31, subject to Board discretion to reduce or eliminate the increase in any given year.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, or contingencies beyond the standard disclosure of the voting results.
Key Facts for Investor Verification
- Verify the specific number of shares added to the 2021 Equity Incentive Plan reserve for the initial increase date.
- Confirm the terms of the re-elected directors' three-year terms expiring in 2026.
- Review the definitive proxy statement dated April 19, 2023, for detailed background on the proposals.
- Note that the filing contains no financial performance data for the period.